Nephrospec™ Neovascularization and Improving Blood Supply

Atherosclerotic renal artery stenosis (ARAS) remains the leading cause of renovascular disease. ARAS causes hypertension, loss of renal function, and cardiovascular complications.

Treatment by means of percutaneous transluminal renal artery stenting (PTRAS) is disappointing in preserving renal function and preventing cardiovascular events.

Microvascular remodelling (rarefaction) is an important pathologic alteration in the stenotic kidney.
PTRAS cannot repair the pre-existed intrarenal damage.

Clinical Conclusions

• LI-ESWT induces upregulation of angiogenic factors and promotes Intrarenal Angiogenesis
• LI-ESWT improves the kidney oxygenation and preserves renal function
• LI-ESWT leads to restoration of the renal microcirculation
• LI-ESWT reduces blood pressure
• LI-ESWT reduced oxidative and fibrotic damages
• No signs of renal damage were detected in SW-treated kidneys

Compact, Mobile & Cost Effective

Nephrospec joins the Medispec line of superior, non-invasive, deep penetration Shock Wave Therapy systems, ensuring a high success rate within a relatively short time frame. It is compact and mobile, making it easy to store and move from room to room. The device is Multi-Purpose, and may be used for treatment of ED, CPPS, as well as other urology, vascular and orthopaedics disorders, all in one unit.

Benefits

• Comfortable, non-invasive treatment requiring no anesthesia
• Deep focused shock wave penetration
• Short treatment time
• Easily performed in clinics and offices
• User-friendly, intuitive technology
• State-of-the-art touch screen
• Compact design and enhanced mobility
• Safe, Non-invasive and effective treatment of the ischemic kidney distal to ARAS